Dabigatran in cardiovascular disease management: A comprehensive review

doi:10.4330/wjc.v13.i12.710

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3308)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

292

WORD

116

HTML

2107

Tables (1-1)

128

Sum=2643

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

254

Download

411

Sum=665

Dec 26, 2021 (publication date) through May 18, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. Dec 26, 2021; 13(12): 710-719
Published online Dec 26, 2021. doi: 10.4330/wjc.v13.i12.710

Dabigatran in cardiovascular disease management: A comprehensive review

Ayesha Javed, Muhammad Ajmal, Aaron Wolfson

Ayesha Javed, Department of Internal Medicine, University of Arizona, Tucson, AZ 85719, United States

Muhammad Ajmal, Department of Cardiology, University of Arizona, Tucson, AZ 85719, United States

Aaron Wolfson, Department of Cardiology, University of Southern California, Los Angeles, CA 90007, United States

Author contributions: Ajmal M came up with the idea; Javed A and Ajmal M drafted the manuscript; Wolfson A reviewed and finalized it; Javed A, Ajmal M and Wolfson A revised the manuscript.

Conflict-of-interest statement: All authors have no any conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Muhammad Ajmal, MD, Academic Fellow, Department of Cardiology, University of Arizona, 1625 N Campbell Ave, Tucson, AZ 85704, United States. drajmal207@gmail.com

Received: April 6, 2021
Peer-review started: April 6, 2021
First decision: September 2, 2021
Revised: September 27, 2021
Accepted: November 25, 2021
Article in press: November 25, 2021
Published online: December 26, 2021

Core Tip

Core Tip: Direct oral anticoagulants (DOACs) have plethora of data for the use in medical field and particulalry in cardiovascular medicine. This review is focused on the dabigatran which is one of the DOAC and it is prudent for all the physicians to be familiar with this drug.